HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Posts Strong Q1 On Selsun Blue Naturals, ACT, Cortisone

This article was originally published in The Tan Sheet

Executive Summary

The success of Selsun Blue Naturals is leading a revival of the Selsun dandruff franchise, fueling its strongest performance in six periods, Chattem said during an April 8 first quarter analyst call

You may also be interested in...



Chattem Plans ACT, Gold Bond, Icy Hot Line Extensions In 2009

In 2009, Chattem will launch the "first legitimate line extension" for ACT mouthwashes since it acquired the brand, according to President and Chief Operating Officer Bob Bosworth

Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli

Chattem has not delivered a counter-punch to GlaxoSmithKline's alli, but the firm sees its Dexatrim supplement as "the only one left standing" to compete in the nonprescription weight-loss product category

Chattem To Unveil New Products In August, Reports 42 Percent Sales Growth

Chattem reported substantially higher sales growth in its latest quarter from brands it acquired in 2006 than from products it developed, but looks to boost those products' contribution to its growth with the launch of nine line extensions in early 2008

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel